Figure 1 | Scientific Reports

Figure 1

From: In vitro activity of antibiotics potentially effective against difficult-to-treat strains of Gram-negative rods: retrospective study

Figure 1

MIC (minimum inhibitory concentration) distributions; A, Cefiderocol non-DTR; B, Cefiderocol DTR; C, Imipenem/cilastatin/relebactam non-DTR; D, Imipenem/cilastatin/relebactam DTR. PSAE, Pseudomonas aeruginosa; ACBA, Acinetobacter baumannii; ENT, Enterobacterales. Dotted lines represent EUCAST 2023 clinical breakpoints of cefiderocol (PSAE, ENT susceptible, MIC ≤ 2 mg/L, ACBA has no clinical breakpoints), imipenem/cilastatin/relebactam (PSAE, ACBA, ENT susceptible, MIC ≤ 2 mg/L).

Back to article page